Literature DB >> 2144544

Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis.

C Leprince1, S Cohen-Kaminsky, S Berrih-Aknin, B Vernet-Der Garabedian, D Treton, P Galanaud, Y Richard.   

Abstract

Thymic cell populations from 12 patients displaying myasthenia gravis were submitted to a phenotypic and functional study. Immunofluorescence analysis of thymic sections revealed the presence in germinal centers of B lymphocytes expressing the B cell markers--CD19, CD21, IgD, or IgM. After T cell and macrophage depletion of thymic single cell suspensions, B cell-enriched populations were isolated. Enriched B cells expressed at variable levels activation markers such as CD71, 4F2, CD23, and B8.7, indicating that a marked proportion of them are activated. Moreover, addition of B cell growth factor 12kDa and to a lesser extent of rIL-2 induced a spontaneous proliferation of these B cell populations. These functional and phenotypic signs of activation may reveal the first steps of an autoimmune response against acetylcholine receptor as enriched B cell populations have the capacity to spontaneously secrete anti-acetylcholine receptor antibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144544

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Analysis of CD4+CD25+ cell population in the thymus from myasthenia gravis patients.

Authors:  A Balandina; A Saoudi; P Dartevelle; S Berrih-Aknin
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

2.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 3.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

Review 5.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

6.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

8.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

Review 9.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

10.  The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Authors:  Amel Meraouna; Geraldine Cizeron-Clairac; Rozen Le Panse; Jacky Bismuth; Frederique Truffault; Chantal Tallaksen; Sonia Berrih-Aknin
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.